Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis
Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis
The primary objective of the trial is to investigate the survival time (the time from randomization until death or end of the trial) compared between control group and experimental group.
- Trial name
- NCT01879241
- Testing
- Rasagiline
- Where
- 15 sites in Germany
- Volunteers
- 252 people
- Sponsor
- University of Ulm
Amyotrophic Lateral Sclerosis (ALS)
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine if oral treatment with ONO-2506PO in patients diagnosed with ALS, who have had onset of muscle weakness within 14 months of randomization, could lead to the slowing of decline in…
- Trial name
- NCT00403104
- Testing
- ONO-2506PO
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 420 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
Cervical Electrical Stimulation for ALS
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). ALS causes degeneration of motor neurons in both the brain and the spinal cord.
- Trial name
- NCT03411863
- Testing
- CES at rest, CES plus active hand or wrist movements
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Spasticity
Long-term Surveillance of the MedStream Programmable Infusion System
This post-approval study will primarily evaluate the long-term safety of the MedStream Programmable Infusion System when used in combination with Baclofen for the treatment of severe spasticity.
- Trial name
- NCT01712087
- Testing
- MedStream Programmable Infusion System
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Codman & Shurtleff
Amyotrophic Lateral Sclerosis
Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons, with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS and remains the main prognostic factor.
- Trial name
- NCT00879593
- Testing
- PtcCO2
- Where
- 2 sites in France
- Volunteers
- 66 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Amyotrophic Lateral Sclerosis (ALS)
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral…
- Trial name
- NCT04577404
- Testing
- MT-1186
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 124 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Study of Electrical Impedance Myography (EIM) in ALS
This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health. The trial is studying people with Amyotrophic Lateral Sclerosis (ALS), other neuromuscular diseases, and healthy volunteers to see if the…
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Charcot-Marie-Tooth Disease, Multiple Sclerosis
- Trial name
- NCT02011204
- Testing
- Electrical impedance myography (EIM)
- Where
- 6 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Skulpt, Inc.
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Cerebral Cortex Dysfunction
Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis
This study will test whether primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS) affect parts of the brain responsible for thinking, planning, memory and emotion.
- Trial name
- NCT00334516
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.
- Trial name
- NCT00596115
- Testing
- R(+) pramipexole dihydrochloride monohydrate
- Sponsor
- Bennett, James P., Jr., M.D., Ph.D.
Amyotrophic Lateral Sclerosis
Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis
To evaluate the safety and effectiveness of intravenous infusion of plasma from healthy young people for the treatment of amyotrophic lateral sclerosis.
- Trial name
- NCT04454840
- Testing
- Plasma from healthy young people treatment + Riluzole, Riluzole
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
Spinal Muscular Atrophy (SMA)
Service Evaluation for Newborn Screening for Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is a disease that causes progressive muscle weakness. There are many types- the most severe and most common, type 1, affects very young babies, and is life-threatening if untreated.
- Trial name
- SENS (NCT07888868)
- Where
- 3 sites in United Kingdom
- Volunteers
- 750,000 people
- Sponsor
- University of Oxford
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
- Trial name
- ONYX (NCT05626855)
- Testing
- Apitegromab
- Where
- 49 sites in United States, Belgium and 7 more
- Volunteers
- 238 people
- Sponsor
- Scholar Rock, Inc.
SMA - Spinal Muscular Atrophy
An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB058)
An Open Label Individual Patient (OLIP) Study of Nusinersen (BIIB058) in a Participant with Spinal Muscular Atrophy Who Previously Participated in an Investigational Study with Nusinersen
- Trial name
- NCT07846696
- Testing
- Nusinersen Injectable Product
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Spinal Muscular Atrophy
Clinical Assessment of Spinal Muscular Atrophy Type II and III (SMA Europe)
The aim of this project is to establish a network of clinical teams including the major neuromuscular centers in Europe. We plan to work together to find the best common outcome measures for the following multicenter therapeutic…
- Trial name
- NCT01611610
- Testing
- Functional tests
- Volunteers
- 4 people
- Sponsor
- Institut de Myologie, France
Spinal Muscular Atrophy
Improving Standards of Care and Translational Research in Spinal Muscular Atrophy (SMA)
The SMA REACH UK Network is a national and international partnership between doctors and therapists involved in the care of children and adults with Spinal Muscular Atrophy. This network is supported by Biogen and SMA UK.
- Trial name
- SMA-REACH (NCT03520179)
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Amyotrophic Lateral Sclerosis
Repetitive Transcranial Magnetic Stimulation as Therapy for Apathy in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of central and peripheral motor neurons. ALS leads to death usually within 3 to 5 years from the onset of the symptoms.
- Trial name
- NCT03892382
- Testing
- rTMS
- Where
- Poland
- Sponsor
- Jagiellonian University
Amyotrophic Lateral Sclerosis
Enoxacin for Amyotrophic Lateral Sclerosis (ALS)
The study will assess the safety of the drug enoxacin at specific dose levels in adults with ALS.
- Trial name
- REALS-1 (NCT04840823)
- Testing
- Enoxacin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McGill University
Amyotrophic Lateral Sclerosis
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
- Trial name
- NCT05633459
- Testing
- Multiple ascending doses of QRL-201, QRL-201
- Where
- 15 sites in Belgium, Canada and 4 more
- Volunteers
- 69 people
- Sponsor
- QurAlis Corporation
Frontotemporal Dementia, Frontotemporal Degeneration
Voices Of Individuals: Challenges and Experiences Of bvFTD
The VOICE Of bvFTD study is a telephone interview research study about life with or at risk for behavioral variant frontotemporal dementia (bvFTD).
- Conditions
- Frontotemporal Dementia, Frontotemporal Degeneration, Frontotemporal Dementia, Behavioral Variant, FTD
- Trial name
- NCT04060082
- Testing
- Telephone Interview
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.